SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION;서울대학교 산학협력단
发明人:
PARK, Chung Gyu,박정규,KIM, Jung Sik,김정식
申请号：
KRKR2018/006327
公开号：
WO2018/222019A1
申请日:
2018.06.01
申请国别(地区):
KR
年份:
2018
代理人:
摘要：
The present invention relates to novel anti-CD40 antibodies and a use thereof and, more specifically, provided are a pharmaceutical composition for treating or preventing autoimmune diseases and a composition for inhibiting immune rejection during organ transplantation, both compositions containing, as an active ingredient, novel anti-CD40 antibodies that specifically bind to a novel epitope of CD40. Novel anti-CD40 antibodies of the present invention directly target CD40, but not CD40 ligands, and block the signaling of CD40-CD154 without stimulating platelets so as to exhibit excellent antagonistic effects, thereby being expected to be usable as a preparation effective in the treatment of autoimmune diseases and the inhibition of organ transplantation rejection.La présente invention concerne de nouveaux anticorps anti-CD40 et leur utilisation et, plus particulièrement, l'invention concerne une composition pharmaceutique pour traiter ou prévenir des maladies auto-immunes et une composition pour inhiber le rejet immunitaire pendant une transplantation d'organe, les deux compositions contenant, en tant que principe actif, de nouveaux anticorps anti-CD40 qui se lient de manière spécifique à un nouvel épitope de CD40. Les nouveaux anticorps anti-CD40 selon la présente invention ciblent directement CD40, mais pas les ligands CD40, et bloquent la signalisation de CD40-CD154 sans stimuler les plaquettes de manière à présenter d'excellents effets antagonistes, ce qui les rend appropriés pour une utilisation en tant que préparation efficace dans le traitement de maladies auto-immunes et l'inhibition du rejet de transplantation d'organe.본 발명은 신규한 항-CD40 항체 및 이의 용도에 관한 것으로, 보다 상세하게는 CD40의 신규 에피토프에 특이적으로 결합하는 신규한 항-CD40 항체를 유효 성분으로 포함하는 자가면역질환의 치료 또는 예방용 약학적 조성물 및 장기이식시 면역거부반응 억제용 조성물을 제공한다. 본 발명의 신규한 항-CD40 항체는 CD40 리간드가 아닌 CD40을 직접 타겟으로 하며, 혈소판을 자극하지 않으면서 CD40-CD154 신호전달을 차단하여 탁월한 길항 효과를 나타내므로 자가면역질환의 치료 및 장기이식 거부반응 억제에 효과적인 제제로 활용될 수 있을 것으로 기대된다.
